Diffuse large B-cell lymphomas
Diffuse large B-cell lymphomas of the waldeyer's ring frequently have a germinal center-like phenotype: a clinico-pathological study of 209 patients from the groupe d'étude des lymphomes de l'adulte (GELA).
1
Diffuse Large B-cell Lymphomas of the waldeyer's ring frequently have a germinal center-like phenotype: a clinico-pathological study of 209 patients from the groupe d'étude des lymphomes de l'adulte (GELA).
2
Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort
14
Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients
12
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
12
Gene expression-based risk score in diffuse large B-cell lymphoma.
12
Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.
9
Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis
13
Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies
8
Diffuse large B-cell lymphoma of Waldeyer's ring has distinc clinicopathologic features: a GELA study.
9
Regulatory myeloid cells: an underexplored continent in B-cell lymphomas
26
Cytolytic T-cell response to the PASD1 cancer testis antigenin patients with diffuse large B-cell lymphoma
12
The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.
23
Role of ETS1 in the transcriptional network of diffuse large B cell lymphoma of the activated B cell-like type
17
A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival
12
Subcutaneous Rituximab-MiniCHOP compared with subcutaneous Rituximab-MiniCHOP plus Lenalidomide in diffuse large B-Cell lymphoma for patients age 80 years or older.
12
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
20
en fr Role of Orai1 and STIM1 in B-cell non-Hodgkin lymphomas, establishment of a new 3D cell culture model. Rôle des protéines Orai1 et STIM1 dans les lymphomes B non-Hodgkiniens, établissement d'un modèle d'étude en 3D.
323
Treatment of mantle cell lymphomas: recommendations of the Belgian Hematological Society
8
CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features
9